Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Hae Il Jung, Dongjun Jeong, Sanghee Ji, et al.
Cancer Research and Treatment (2016) Vol. 49, Iss. 1, pp. 246-254
Open Access | Times Cited: 184

Showing 51-75 of 184 citing articles:

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
Cedric Brackenier, Lisa Kinget, Sarah Cappuyns, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 348-348
Open Access | Times Cited: 12
Programmed cell death-ligand 2: new insights in cancer
Yukang Yang, Yan Xia, Xueqi Bai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Characterization of Early Lesions of Human Post-Primary Tuberculosis and Its Progression to Necrosis Using Archival Material of the Pre-Antibiotic Era
Syeda Mariam Riaz, Kurt Hanevik, Lisbet Sviland, et al.
Pathogens (2025) Vol. 14, Iss. 3, pp. 224-224
Open Access
Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate
Gabriel Fridolin Hess, Caner Ercan, Alexander Wilhelm, et al.
Pathobiology (2025), pp. 1-12
Open Access
Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
Gao‐Min Liu, Xu-Gang Li, Yao-Min Zhang
Cancer Cell International (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 30
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1
Naoshi Nishida, Kazuko Sakai, Masahiro Morita, et al.
Liver Cancer (2020) Vol. 9, Iss. 4, pp. 426-439
Open Access | Times Cited: 30
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions
Yu Toda, Kenichi Kohashi, Yuichi Yamada, et al.
Journal of Cancer Research and Clinical Oncology (2020) Vol. 146, Iss. 10, pp. 2607-2620
Open Access | Times Cited: 30
High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
Ryo Muranushi, Kenichiro Araki, Takehiko Yokobori, et al.
Cancer Science (2021) Vol. 112, Iss. 8, pp. 3314-3323
Open Access | Times Cited: 24
Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
Alice Boilève, Marc Hilmi, Matthieu Delaye, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2708-2708
Open Access | Times Cited: 24
Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
Vishakha Singh, Amit Khurana, Prince Allawadhi, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 24
Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach
Eslam E. Abd El-Fattah, Amr Y. Zakaria
International Immunopharmacology (2022) Vol. 109, pp. 108889-108889
Closed Access | Times Cited: 18
Navigating through the PD-1/PDL-1 Landscape: A Systematic Review and Meta-Analysis of Clinical Outcomes in Hepatocellular Carcinoma and Their Influence on Immunotherapy and Tumor Microenvironment
Muhammad Joan Ailia, Jeong Heo, So Young Yoo
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6495-6495
Open Access | Times Cited: 10
Autophagy as a Target for Non-Immune Intrinsic Functions of Programmed Cell Death-Ligand 1 in Cancer
Blanca Estela García‐Pérez, Christian Pérez-Torres, Shantal Lizbeth Baltierra‐Uribe, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 15016-15016
Open Access | Times Cited: 10
Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells
Sua Cho, Wonjin Kim, Dayoung Yoo, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Immunophenotypes and Tumor Immune Microenvironment in Hepatocellular Carcinoma With Macrotrabecular Massive and Vessels Encapsulating Tumor Clusters
Jun Akiba, Masamichi Nakayama, Reiichiro Kondo, et al.
In Vivo (2024) Vol. 38, Iss. 2, pp. 640-646
Open Access | Times Cited: 3
Extracellular Vesicle-Related Non-Coding RNAs in Hepatocellular Carcinoma: An Overview
Giuseppa Augello, Alessandra Cusimano, Melchiorre Cervello, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1415-1415
Open Access | Times Cited: 3
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
Jinghua Li, Weijie Ma, Ganggang Wang, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 32
High expression of B7‑H2 or B7‑H3 is associated with poor prognosis in hepatocellular carcinoma
Youshi Zheng, Naishun Liao, Yuan Wu, et al.
Molecular Medicine Reports (2019)
Open Access | Times Cited: 27
PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer
Xiaoli Wei, Xuan Luo, Hui Sheng, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 27
Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
Christian Ihling, Bartholomew J. Naughton, Yue Zhang, et al.
Frontiers in Medicine (2019) Vol. 6
Open Access | Times Cited: 26
TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
Ritu Shrestha, Kim R. Bridle, Dorothy H. Crawford, et al.
Molecular Medicine Reports (2020)
Open Access | Times Cited: 26
The roles of programmed death ligand 1 in virus-associated cancers
Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
Infection Genetics and Evolution (2020) Vol. 84, pp. 104368-104368
Closed Access | Times Cited: 25
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
Yanjie Zhao, Feng Shi, Quan Zhou, et al.
Medicine (2020) Vol. 99, Iss. 45, pp. e23172-e23172
Open Access | Times Cited: 24
Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
Min Luo, Yan Lin, Rong Liang, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 4217-4228
Open Access | Times Cited: 23
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
Dagmar Kollmann, Thomas Schweiger, Stefan Schwarz, et al.
OncoImmunology (2017) Vol. 6, Iss. 9, pp. e1331194-e1331194
Open Access | Times Cited: 25

Scroll to top